Replies to post #428674 on Anavex Life Sciences Corp (AVXL)

[bas2020]

If Missling didn't believe that an approval pathway is forthcoming, he wouldn't be talking commercialization nor would he mention the possibility of the AD OLE serving as the confirmatory trial. He likely has had conversations with the FDA about it for him to make such a statement.

[LBSR TO DA MOON]

Investor2014 - What share price and/or MC do you think AVXL can attain on truly excellent EXCELLENCE results? On NDA submission? On FDA approval?

Also, if you turn out to be delightfully wrong, what share price and/or MC do you think AVXL can attain?

But if it turns out to be deemed a P3 registration trial by the FDA for traditional approval, then of course I and some others will be proven delightfully wrong.

Lastly, if AVXL actually achieves AA, what share price and/or MC do you think it can attain?

On the other hand if a P2b with or without AA potential with surrogate endpoint biomarker(s), then the endpoint judgement criteria falls more to the wayside as a lesser issue. I and a few others will the been proven correct that it was not a pivotal P3 meeting all endpoints for traditional approval. If we then in fact achieved AA I will also be delighted.

[sab63090]

I think your thoughts on this are pretty close to being correct no matter how this works out!

It gives those who are in doubt reasonable reasons to be cautious since normal data release has NOT happened; and for those very optimistic to see how it shakes out...everyone is pretty much locked in on what will happen, but I am thinking this RETT Excellence Trial will make things clearer. at least for me.

Yes, I'm biased to the long side with a large dose of "hopium"....ha ha

I am amazed that the big shakeout below $7.30 to $7.50 has not happened to break psychology even if it might be a false one....